SOLIGENIX, INC. Debt Conversion, Converted Instrument, Amount
SOLIGENIX, INC. (SNGX) reported Debt Conversion, Converted Instrument, Amount of $254.26 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-03-31
- SOLIGENIX, INC. debt conversion, converted instrument, amount for the quarter ending 2024-12-31 was $0.00.
- SOLIGENIX, INC. debt conversion, converted instrument, amount for the quarter ending 2024-09-30 was $0.00.
- SOLIGENIX, INC. debt conversion, converted instrument, amount for the quarter ending 2024-06-30 was $154.84K.
- SOLIGENIX, INC. debt conversion, converted instrument, amount for the quarter ending 2024-03-31 was $99.42K.
- SOLIGENIX, INC. debt conversion, converted instrument, amount for fiscal 2024 was $254.26K.
- SOLIGENIX, INC. debt conversion, converted instrument, amount for fiscal 2012 was -$429.90K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $154.84K derived: sum of 3 quarters · filed 2026-03-31 | $254.26K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $154.84K derived: sum of 2 quarters · filed 2025-11-07 | $254.26K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $154.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $254.26K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $99.42K 10-Q · filed 2025-05-09 | |||
| 2012-12-31 | -$429.90K 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |